Microneedling Combined With Drugs and Stem Cells for Treating Androgenetic Alopecia

The document discusses the use of microneedling (MN) combined with drugs and stem cells as a treatment for androgenetic alopecia (AGA). MN is effective for transdermal drug delivery, particularly with 5% minoxidil or clascoterone solution, and is safe with minimal side effects. The procedure involves using a dermaroller with 1.5 mm needles on a shaved scalp, followed by drug application 24 hours later. Sessions every 4 weeks for 3 to 12 months show significant improvement in hair density and thickness in about 80% of patients. Stem cell-based therapies, though not FDA approved, are gaining attention for reactivating hair follicle stem cells and improving hair growth. These therapies, combined with MN, show promise but require further investigation and standardized protocols. The document suggests that combining these treatments with conventional therapies could offer personalized strategies for managing severe AGA.